Core Viewpoint - Yuyuan Pharmaceutical's subsidiary has received FDA approval for clinical trials of YKYY018 aerosol inhalation solution aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] Group 1: Company Developments - Yuyuan Pharmaceutical announced that its wholly-owned subsidiary, Beijing Yuyuan Kete Pharmaceutical Technology Co., Ltd., has obtained FDA consent for clinical trials of YKYY018 [1] - The drug YKYY018 is a membrane fusion inhibitor that specifically binds to the HR1 region of the RSV fusion protein, blocking the fusion process between the virus and host cells [1] Group 2: Product Details - YKYY018 aerosol inhalation solution has dual functions for both treatment and prevention of RSV infections [1] - The mechanism of action involves inhibiting the formation of the homologous 6-HB structure between HR1 and HR2 domains of the virus [1]